基于常规临床指标得出的β细胞功能可报告并预测新发1型糖尿病对免疫治疗的反应
研究利用BANDIT随机试验数据,评估由常规临床和生化指标得出的β细胞功能指标能否报告和预测巴瑞替尼治疗反应。定量反应评分、空腹C肽和模型估算C肽最能区分安慰剂组与巴瑞替尼组;基于12周空腹血糖、C肽、HbA1c和胰岛素剂量得出的Beta2评分可预测治疗反应,并在利妥昔单抗、阿巴西普和抗胸腺细胞球蛋白试验中验证。
要点
- 定量反应评分、空腹C肽和模型估算C肽在24周和48周最能区分安慰剂组与巴瑞替尼组。
- 12周Beta2评分预测巴瑞替尼治疗1年后定量反应评分>0的曲线下面积为0.864。
- Beta2评分在其他免疫治疗中预测定量反应评分>0的曲线下面积为0.765。
核心结论
- 定量反应评分、空腹C肽和模型估算C肽可作为未来免疫治疗试验更高效、负担更轻的主要结局指标。
- Beta2评分预测治疗反应的能力可促进适应性试验设计,并有助于指导临床治疗决策。
研究设计与样本
- 研究使用巴瑞替尼治疗新诊断1型糖尿病随机试验(BANDIT)的数据计算由临床和生化指标得出的β细胞功能指标。
- 使用线性回归和受试者工作特征分析分别确定能报告和预测治疗疗效的指标。
- 治疗预测指标使用利妥昔单抗、阿巴西普和抗胸腺细胞球蛋白试验的数据进行验证。
主要发现
- 定量反应评分、空腹C肽和模型估算C肽在24周和48周最能可靠区分安慰剂组与巴瑞替尼组。
- 由12周空腹血糖、C肽、HbA1c和胰岛素剂量得出的Beta2评分,对预测巴瑞替尼治疗1年后定量反应评分>0最佳,曲线下面积为0.864。
- Beta2评分对其他免疫治疗预测定量反应评分>0的曲线下面积为0.765。
- 12周Beta2评分下降6.2%可预测利妥昔单抗、阿巴西普和抗胸腺细胞球蛋白试验合并数据中HbA1c(-0.6%或-6 mmol/mol)和胰岛素用量(-0.26单位/kg/天)的显著改善。
关键数值与推荐
- Beta2评分预测巴瑞替尼治疗1年后定量反应评分>0的曲线下面积为0.864。
- Beta2评分预测其他免疫治疗定量反应评分>0的曲线下面积为0.765。
- 12周Beta2评分下降6.2%预测合并免疫治疗试验中HbA1c降低0.6%(或6 mmol/mol)和胰岛素用量降低0.26单位/kg/天。
临床怎么用
- 定量反应评分、空腹C肽和模型估算C肽可作为未来免疫治疗试验更高效、负担更轻的主要结局指标。
- Beta2评分预测治疗反应的能力可促进适应性试验设计,并有助于指导临床治疗决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Baricitinib preserves β-cell function in people with recently diagnosed type 1 diabetes. We aimed to determine whether simple routine clinical measures could be used to assess β-cell preservation and predict treatment response. RESEARCH DESIGNS AND METHOD: Measures of β-cell function derived from clinical and biochemical measures were calculated using data from the BAricitinib in Newly DIagnosed Type 1 diabetes (BANDIT) randomized trial of baricitinib in recent-onset type 1 diabetes. Measures that reported and predicted treatment efficacy were determined using linear regression and receiver operator characteristic analysis, respectively. Therapeutic predictors were validated using data from trials of rituximab, abatacept, and antithymocyte globulin. RESULTS: Quantitative response score (QRS), fasting C-peptide, and model-estimated C-peptide (CPest) most reliably differentiated placebo-treated from baricitinib-treated participants at 24 and 48 weeks. The Beta2 score, derived from fasting glucose, C-peptide, HbA1c, and insulin dose at 12 weeks, was optimal for predicting QRS >0 following 1 year of treatment with baricitinib and the other immunotherapies (areas under receiver operator curve 0.864 and 0.765, respectively). A 6.2% decrease in the Beta2 score at week 12 predicted significant improvement in HbA1c (-0.6% or -6 mmol/mol) and insulin use (-0.26 units/kg/day) in combined data from the rituximab, abatacept, and antithymocyte globulin trials. CONCLUSIONS: QRS, fasting C-peptide, and CPest could be used as more efficient, less burdensome primary outcome measures for future immunotherapy trials. The ability of the Beta2 score to predict treatment responses could facilitate adaptive trial designs and help guide treatment decisions in the clinic.
引用
- So M, Vogrin S, Waibel M, et al. β-Cell Function Derived From Routine Clinical Measures Reports and Predicts Treatment Response to Immunotherapy in Recent-Onset Type 1 Diabetes. Diabetes Care. 2025. PMID: 40424079. doi:10.2337/dc25-0565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。